Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.
about
Origin and molecular pathogenesis of ovarian high-grade serous carcinomaRecent concepts of ovarian carcinogenesis: type I and type IIMutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.The disparate origins of ovarian cancers: pathogenesis and prevention strategies.TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.Paraneoplastic Neurological Syndrome in Fallopian Tube CancerExploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancerMutant p53 expression in fallopian tube epithelium drives cell migrationStathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinomaOvarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report.Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma.Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.Early preinvasive lesions in ovarian cancer.Subtypes of Ovarian Cancer and Ovarian Cancer Screening.DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression.LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol.Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double EffectUnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer
P2860
Q26852698-4BD24D8A-B784-48D1-A1D4-E8A32614BBA1Q27009487-DB4E8934-125D-44BF-987B-34BF27CA5E92Q27333756-7DB8A642-920D-4CC5-A052-63333E71FAE5Q30240709-0178551A-C802-4CA1-A10B-63870CC9D201Q34223292-6BA8985D-7C9F-475C-8223-F12D1DC70389Q34409354-74470EEB-D96C-45E4-A518-9E83CC1489B2Q34579904-D0E21E32-4034-4D72-B294-910B3DB6B6BAQ35035679-D8BDE009-0007-4AA2-9864-339E23C2D21BQ35855276-0BBCB140-E745-46E3-8EE9-AD24424511CEQ36103306-93923963-446B-4D0F-9222-B4ED7186FA04Q36285968-44645FF8-E3C5-4B67-B50C-C37163521C0CQ36662048-150A57AC-EFB3-4579-B40E-6B22FA735C09Q36889642-40D422A2-D2D3-4F76-8BA5-05FA52F3D80CQ37023858-6DFBE668-8768-4A85-AD26-B4E9D2F79F5EQ37287587-13598256-510B-4128-89A1-73D1D6BC858CQ37512375-8775EAB3-5D95-4471-A309-4A303C7FC5F4Q37553978-62A089E3-9D68-4E8D-BAF4-83DCDF701647Q37626525-382129F2-7211-4654-825C-54EAF8B85752Q37719090-EF48499C-3D63-4ACF-814B-5CDB5EE21522Q37729974-41F6EE74-B57A-4537-A7FC-99685F10EDDAQ38790328-80B31BE1-EF4E-472A-9119-C593F51DD83EQ40140028-F7314C26-E6A7-401F-8072-00422848F44FQ42379619-7D9B6F5B-7613-42D5-BCC0-02D3BCD0900FQ43703057-49D7CC0E-FA64-409D-8512-86CA7D49FA8DQ50101328-CA8BBC87-F7F7-4EEB-9D7A-38B467A8EA12Q54204521-516F0838-EFC5-4B40-AB9F-E5EFFC8D72EFQ57137351-7E6E450D-15A0-4F20-8D21-907DF3651E36Q58795166-FD5721FC-E2D0-4966-B060-130D50F6F1F9
P2860
Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Precursor lesions of high-grad ...... and molecular characteristics.
@ast
Precursor lesions of high-grad ...... and molecular characteristics.
@en
type
label
Precursor lesions of high-grad ...... and molecular characteristics.
@ast
Precursor lesions of high-grad ...... and molecular characteristics.
@en
prefLabel
Precursor lesions of high-grad ...... and molecular characteristics.
@ast
Precursor lesions of high-grad ...... and molecular characteristics.
@en
P2093
P2860
P356
P1433
P1476
Precursor lesions of high-grad ...... and molecular characteristics.
@en
P2093
Amy L Gross
Ie-Ming Shih
Kala Visvanathan
Robert J Kurman
Russell Vang
P2860
P304
P356
10.1155/2010/126295
P577
2010-04-27T00:00:00Z